Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures

Acta Oto-Laryngologica

Volumn 134, Issue 5, 2014, Pages 448-454

  Dammeyer, Pascal ^a   Hellberg, Victoria ^b   Wallin, Inger ^b   Laurell, Göran ^c   Shoshan, Maria ^b   Ehrsson, Hans ^b   Arnér, Elias S J ^a   Kirkegaard, Mette ^d  

^a Division of Biochemistry   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Animal model; Cochlear organotypic culture; Ototoxicity; Platinum drugs

Indexed keywords

CISPLATIN; OXALIPLATIN; THIOREDOXIN REDUCTASE; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; CORTI ORGAN; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HAIR CELL; HAIR LOSS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; NONHUMAN; ORGAN CULTURE; OTOTOXICITY; PRIORITY JOURNAL; RAT; TOXICITY TESTING; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; GUINEA PIG; METABOLISM; ORGAN CULTURE TECHNIQUE; SPRAGUE DAWLEY RAT; TOXICITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; GUINEA PIGS; HAIR CELLS, AUDITORY, OUTER; ORGAN CULTURE TECHNIQUES; ORGANOPLATINUM COMPOUNDS; RATS, SPRAGUE-DAWLEY; THIOREDOXIN-DISULFIDE REDUCTASE;

EID: 84897985377     PISSN: 00016489     EISSN: 16512251     Source Type: Journal    
DOI: 10.3109/00016489.2013.879740     Document Type: Article

References (20)

1. Knight KR, Kraemer DF, Winter C, Neuwelt EA. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007;25:1190-5. (Pubitemid 46640564)
2. Pasetto LM, D'Andrea MR, Rossi E, Monfardini S. Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 2006;59:159-68. (Pubitemid 44094106)
3. Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, et al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009;101:37-47.
4. van Ruijven MW, de Groot JC, Hendriksen F, Smoorenburg GF. Immunohistochemical detection of plati-nated DNA in the cochlea of cisplatin-treated guinea pigs. Hear Res 2005;203:112-21. (Pubitemid 40602821)
5. Wang D, Lippard SJ. Cellular processing of platinum anti-cancer drugs. Nat Rev Drug Discov 2005;4:307-20. (Pubitemid 41130944)
6. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003;278: 9100-6. (Pubitemid 36800390)
7. Kopke RD, Liu W, Gabaizadeh R, Jacono A, Feghali J, Spray D, et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 1997;18:559-71. (Pubitemid 27428342)
8. Kim SJ, Park C, Han AL, Youn MJ, Lee JH, Kim Y, et al. Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Hear Res 2009;251: 70-82.
9. Gromer S, Urig S, Becker K. The thioredoxin system-from science to clinic. Med Res Rev 2004;24:40-89.
10. Sun QA, Zappacosta F, Factor VM, Wirth PJ, Hatfield DL, Gladyshev VN. Heterogeneity within animal thioredoxin reductases. Evidence for alternative first exon splicing. J Biol Chem 2001;276:3106-14.
11. Witte AB, Anestal K, Jerremalm E, Ehrsson H, Arner ES. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic Biol Med 2005;39:696-703. (Pubitemid 41112110)
12. Arner ES, Nakamura H, Sasada T, Yodoi J, Holmgren A, Spyrou G. Analysis of the inhibition of mammalian thior-edoxin, thioredoxin reductase, and glutaredoxin by cis-diamminedichloroplatinum (II) and its major metabolite, the glutathione-platinum complex. Free Radic Biol Med 2001;31:1170-8. (Pubitemid 33052492)
13. Becker K, Herold-Mende C, Park JJ, Lowe G, Schirmer RH. Human thioredoxin reductase is efficiently inhibited by (2, 2': 6', 2' '-terpyridine)platinum(II) complexes. Possible implications for a novel antitumor strategy. J Med Chem 2001;44:2784-92. (Pubitemid 32879719)
14. Skjonsberg A, Bucinskaite V, Laurell G, Ulfendahl M. Augmented ototoxic effect of cisplatin in heterozygotes of the German waltzing guinea pig. Audiol Neurootol 2008;13:97-104. (Pubitemid 351225888)
15. Anestål K, Prast-Nielsen S, Cenas N, Arnér ES. Cell death by SecTRAPs: thioredoxin reductase as a prooxidant killer of cells. PLoS One 2008;3(4):e1846.
16. Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B, et al. Organic cation transporter 2 mediates cisplatin-induced oto-and nephrotoxicity and is a target for protective interventions. Am J Pathol 2010;176:1169-80.
17. Urig S, Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol 2006;16: 452-65. (Pubitemid 44780136)
18. Rybak LP, Husain K, Morris C, Whitworth C, Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 2000;21:513-20. (Pubitemid 30432460)
19. Ekborn A, Lindberg A, Laurell G, Wallin I, Eksborg S, Ehrsson H. Ototoxicity, nephrotoxicity and pharmacokinet-ics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol 2003;51:36-42. (Pubitemid 36057021)
20. Laurell G, Bagger-Sjoback D. Degeneration of the organ of Corti following intravenous administration of cisplatin. Acta Otolaryngol 1991;111:891-8.